Xalfu-XL: Main Uses and Clinical Benefit

Xalfu-XL is approved for the treatment of benign prostatic hyperplasia (BPH). This medication is clinically indicated to alleviate the signs and symptoms associated with an enlarged prostate.

Clinical Applications

The primary therapeutic use of Xalfu-XL is to address urinary symptoms caused by BPH. The drug works to manage the discomfort and functional limitations that can arise from this condition. By treating BPH, Xalfu-XL can help improve urine flow and reduce the frequency of urination, including nocturnal episodes. Its benefit is directly tied to the symptomatic relief it provides in the lower urinary tract.

This medication is not indicated for the treatment of high blood pressure, and a medical assessment should be completed to exclude prostate carcinoma before initiating therapy.

---

Quick Facts

• Condition Treated: Benign prostatic hyperplasia (BPH).
• Therapeutic Goal: To manage the signs and symptoms of BPH.
• Clinical Benefit: Improvement in urine flow and reduction in urinary frequency symptoms.

Who Can and Cannot Use Xalfu-XL?

The population eligibility for Xalfu-XL (Alfuzosin hydrochloride extended-release) is strictly defined by regulatory bodies and must align with the official prescribing information.

Approved and Restricted Populations

Classification	Eligible Groups/Conditions
Approved Population	Adult men diagnosed with Benign Prostatic Hyperplasia (BPH).
Age Restriction	Not indicated for pediatric patients (under 18 years); safety and effectiveness are not established.
Conditional Use	Patients with severe renal impairment (creatinine clearance le 30 mL/min) must use the medicine with caution.

---

Absolute Contraindications

Xalfu-XL must not be used in specific patient groups due to regulatory contraindications:

• Patients with known hypersensitivity to alfuzosin or any component of the formulation.
• Individuals with moderate to severe hepatic impairment (Child-Pugh categories B and C).
• Patients taking other alpha-1 blockers concurrently.
• Patients taking potent CYP3A4 inhibitors (e.g., ketoconazole or ritonavir).
• Use in women, including those who are pregnant or lactating, is not indicated nor recommended.

Interactions with other medicines and products

Xalfu-XL (Alfuzosin hydrochloride extended-release) has officially documented interaction patterns that lead to specific restrictions and conditions for use, as defined by regulatory authorities.

Pharmacokinetic and Pharmacodynamic Restrictions

Contraindicated Combinations

Co-administration is prohibited with the following due to clinically significant interaction risk:

• Potent CYP3A4 Inhibitors: These medicines, such as ketoconazole, itraconazole, and ritonavir, significantly inhibit the metabolic clearance of Alfuzosin. This pharmacokinetic interaction increases Alfuzosin exposure (AUC and C max) several fold.
• Other Alpha-1 alpha1-blockers: Co-administration with other alpha-1 antagonists is prohibited due to the risk of severe, additive hypotensive effects (pharmacodynamic interaction).

Use-With-Caution Combinations

Caution is advised when co-administering Xalfu-XL with anti-hypertensive medicinal products or vasodilators like Nitrates and Phosphodiesterase-5 (PDE-5) Inhibitors. This combination increases the risk of symptomatic hypotension due to the additive blood pressure-lowering effects.

Condition-Based Constraints

• Food Requirement: The medicine must be taken with food to ensure consistent and adequate systemic drug exposure. Regulatory information notes that absorption is significantly lower when taken in a fasted state.
• Hepatic Impairment: Xalfu-XL is contraindicated in severe hepatic impairment because reduced clearance in this patient population substantially increases Alfuzosin plasma concentrations.

Xalfu-XL is a selective inhibitor of the prostaglandin E2 (PGE2) synthase type 1 (PTGES1) enzyme, a key component in the inflammatory cascade.

The compound acts by binding non-competitively to the allosteric site of PTGES1, resulting in reduced production of the signaling molecule PGE2.

This molecular action initiates a cascade that modulates the balance between bone formation and resorption at the system level. By lowering the local concentration of PGE2, Xalfu-XL influences the downstream pathway that regulates osteoclast activity. This specifically leads to decreased osteoclast differentiation and activity. Furthermore, the compound's selectivity for PTGES1 avoids activity at other cyclooxygenase targets, focusing the effect on the intended pathway.

How to Use Xalfu-XL: Official Administration Guidelines

Xalfu-XL (Alfuzosin 10 mg Extended-Release Tablets) is a prescription medicine intended for oral administration only. The method of use is designed to ensure the correct release and absorption of the active ingredient.

---

Standard Dosing and Frequency

Parameter	Official Instruction (Adults)
Route of Administration	Oral (by mouth)
Standard Daily Dose	10 mg
Dosing Frequency	Once daily

---

Administration Conditions

To ensure proper use, the tablet must be administered correctly:

• With Food: Xalfu-XL must be taken immediately after the same meal each day (e.g., dinner). Taking the medicine with food is a mandatory condition, as absorption is significantly reduced when taken on an empty stomach.
• Tablet Integrity: The extended-release tablet must be swallowed whole with a sufficient amount of liquid. It is strictly forbidden to crush, chew, split, or alter the tablet, as this compromises the controlled, sustained release of the drug.

---

Use in Specific Populations

Specific restrictions and recommendations exist for certain patient groups:

• Hepatic Impairment: The 10 mg formulation is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B and C).
• Renal Impairment: Use is generally not recommended in patients with severely impaired renal function (creatinine clearance less than 30 mL/min).
• Pediatric Use: The medication is not indicated for use in children.
• Missed Dose: If a dose is missed, patients should resume the regimen by taking the next scheduled tablet with food the following day. Two tablets should not be taken to compensate for a missed dose.

Research Evidence / Overview of Studies for Xalfu-XL

---

Evidence for Use in Symptomatic Benign Prostatic Hyperplasia (BPH)

The clinical research base for Xalfu-XL is primarily composed of Randomized Controlled Trials (RCTs). These studies were designed to compare the medication to a placebo (an inactive substance) to track patterns in patient groups. Research examined adult men, typically aged ge 50 years, who were diagnosed with Lower Urinary Tract Symptoms (LUTS) associated with BPH.

The main focus of these studies was to monitor outcomes related to physical discomfort and functional imbalance in the lower urinary system. This involved researchers monitoring changes in patient-reported outcomes, such as the International Prostate Symptom Score (IPSS). Studies also monitored objective functional measures, such as the Peak Urinary Flow Rate (Q max), to assess changes in the outflow of urine, and recorded changes in the Post-Void Residual (PVR) urine volume (the amount of urine remaining after urination).

Studies documented changes measured in the IPSS and Q max during the short-term study period. Research explores how symptoms evolved in the observed populations, and the evidence contributes to the broader evidence landscape.

---

Long-Term Studies and Follow-Up Data

Initial controlled research generally focused on research exploring short-term symptom changes over a period of about 12 weeks. To gather more comprehensive information, many patients went on to participate in long-term open-label extension studies or observational studies which continued for periods ranging from six months up to two years.

Researchers monitored outcomes in these long-term settings and collected data on potential BPH progression events. Progression events included outcomes such as the occurrence of Acute Urinary Retention (AUR) episodes or the incidence of BPH-related surgery. This evidence provides insight into outcomes over longer, defined time intervals, and data show patterns related to how symptoms and progression events were observed. However, findings were mixed across studies regarding the specific rate of AUR occurrences.

---

Evidence in Special Populations

The research included in the regulatory assessment primarily focused on a broad group of adult men with symptomatic BPH. Studies explored specific subgroups to understand the applicability of the findings.

For instance, the clinical trials for Xalfu-XL also included men who were also receiving antihypertensive treatment or who had concomitant cardiovascular conditions. This was relevant in trials assessing short-term or episodic symptom patterns in patients with varying symptom burdens and multiple health considerations. The results apply only to the populations studied, and research does not determine whether an individual outside these groups experienced similar patterns.

---

What is Still Uncertain About Xalfu-XL Research

While extensive short-term data exists, long-term effects are not fully established with the same level of certainty as the initial symptom findings. There is limited information for long-term outcomes extending beyond two years.

Furthermore, evidence derived from studies exploring outcomes related to the size of the prostate gland remains inconsistent or inconclusive, as this was not the primary outcome of the main regulatory trials.

Additionally, data for certain groups remain insufficient. Findings were mixed across studies when research explored outcomes related to the long-term risk of developing Acute Urinary Retention. The findings reflect group patterns, not personal outcomes, and evidence highlights what is known—and what is still uncertain—about the medication's role in the overall clinical progression of BPH.

Common questions about Xalfu-XL (FAQ)

Q: What is Xalfu-XL and what is its approved use?

A: Xalfu-XL is a medication approved for the management of symptoms associated with benign prostatic hyperplasia (BPH) in men. It belongs to a class of drugs known as alpha-1 blockers.

---

Q: How was the effectiveness of Xalfu-XL studied in clinical trials?

A: Clinical trials have primarily investigated the effects of Xalfu-XL on improving urinary flow rates and reducing symptoms such as hesitancy, incomplete emptying, and frequent urination in men diagnosed with BPH. The primary objective of these studies was to observe the changes in symptom scores and objective measures of urinary flow.

---

Q: Are there common observations reported regarding the use of Xalfu-XL?

A: Reports from clinical study participants may include experiences of dizziness or fatigue. These observations are generally temporary and tend to lessen with continued use. It is important to discuss any observed effects with a healthcare provider.

---

Q: Can Xalfu-XL affect blood pressure?

A: The mechanism by which Xalfu-XL is studied suggests a potential effect on certain receptors that can influence blood pressure. A temporary decrease in blood pressure has been an observed finding in a portion of study participants, particularly when moving from a sitting or lying position to standing. Monitoring blood pressure may be part of the care plan established by a healthcare professional.

---

Q: What is the typical storage guidance for Xalfu-XL?

A: Xalfu-XL is typically recommended to be stored at room temperature, away from moisture and heat, in its original container. All medications should be kept out of the reach of children.

How to Store and Dispose of Xalfu-XL?

The official storage and disposal requirements for Xalfu-XL (Alfuzosin Extended-Release Tablets) are defined by government regulatory documents to ensure product stability and safety.

---

Official Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature (20 C to 25 C or 68 F to 77 F).
Handling	The extended-release tablets must not be crushed, chewed, or split.
Environment	Keep away from excess heat, moisture, light, and freezing conditions.
Packaging	Store in the original, tightly closed container.

---

Child Safety and Disposal

To ensure safety, Xalfu-XL must be stored out of the sight and reach of children.

When disposing of unused or expired medicine, follow official guidance by utilizing a drug take-back program. The medicine must not be flushed down the toilet or poured down a sink. If a take-back program is unavailable, follow prescribed instructions for mixing the product with an undesirable substance before discarding it in the household trash.